603368.SHG Guangxi Liuzhou Pharm Co Ltd
- Market cap
- CNY 6.83B
- P/E
- 11.7x
- P/B
- 0.88x
- ROE
- 9.2%
- Dividend yield
- 6.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603368.SHG undervalued?
Graham number603368.SHG trades 32.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangxi Liuzhou Pharm Co Ltd fundamental analysis
No fundamental analysis for Guangxi Liuzhou Pharm Co Ltd yet.
Guangxi Liuzhou Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangxi Liuzhou Pharm Co Ltd
Guangxi LiuYao Group Co., Ltd engages in the manufacturing, wholesale, and retail of pharmaceutical products in China. It offers various types of medicines, medical devices, consumables, diagnostic reagents, other innovative drugs, and self-produced products through online pharmacies and terminal physical pharmacies. The company also offers health consultations and engages in food manufacturing. Guangxi LiuYao Group Co., Ltd was founded in 1981 and is based in Liuzhou, China.
Full company profileGuangxi Liuzhou Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangxi Liuzhou Pharm Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.56B | 9.45B | 11.7B | 14.9B | 15.7B | 17.1B | 19.1B | 20.8B | 21.2B | 20.9B | 21.5B |
| Gross Profit | 702M | 894M | 1.24B | 1.77B | 1.91B | 1.92B | 2.15B | 2.44B | 2.38B | 2.31B | 2.24B |
| Operating Income | 402M | 507M | 666M | 897M | 905M | 753M | 890M | 1.04B | 1.00B | 1.15B | 1.08B |
| EBITDA | 401M | 536M | 739M | 1.07B | 1.14B | 1.02B | 1.20B | 1.38B | 1.33B | 1.29B | 1.03B |
| Net Income | 321M | 401M | 528M | 685M | 712M | 564M | 702M | 850M | 855M | 709M | 742M |
| EPS | 1.19 | 1.11 | 1.46 | 1.89 | 1.97 | 1.56 | 1.94 | 2.35 | 2.21 | 1.79 | 1.87 |
| Balance Sheet | |||||||||||
| Total Assets | 6.28B | 7.55B | 9.77B | 12.0B | 14.8B | 15.9B | 18.6B | 20.2B | 21.3B | 21.3B | 20.8B |
| Total Liabilities | 3.04B | 3.99B | 5.73B | 7.30B | 9.36B | 10.1B | 12.2B | 13.1B | 13.3B | 13.2B | 12.4B |
| Shareholders' Equity | 3.19B | 3.49B | 3.85B | 4.37B | 5.10B | 5.46B | 5.97B | 6.62B | 7.62B | 7.83B | 8.07B |
| Cash & Short-term Investments | 1.72B | 1.07B | 1.24B | 1.92B | 3.50B | 3.42B | 3.85B | 3.47B | 3.68B | 3.79B | 2.99B |
| Total Debt | 263M | 624M | 1.75B | 2.25B | 3.63B | 3.92B | 4.34B | 4.42B | 4.08B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 108M | -333M | 22.3M | 413M | 665M | 333M | 506M | 594M | 839M | 1.08B | - |
| Capital Expenditure | 127M | 190M | 272M | 250M | 262M | 264M | 183M | 173M | 148M | 184M | 147M |
| Free Cash Flow | -18.9M | -522M | -249M | 163M | 403M | 68.8M | 323M | 421M | 691M | 893M | 104M |
| Ratios | |||||||||||
| ROE | 10.1% | 11.5% | 13.7% | 15.7% | 14.0% | 10.3% | 11.8% | 12.8% | 11.2% | 9.1% | 9.2% |
| ROA | 5.1% | 5.3% | 5.4% | 5.7% | 4.8% | 3.6% | 3.8% | 4.2% | 4.0% | 3.3% | 3.6% |
| Net Profit Margin | 4.2% | 4.2% | 4.5% | 4.6% | 4.5% | 3.3% | 3.7% | 4.1% | 4.0% | 3.4% | 3.4% |
| Debt to Equity | 0.08x | 0.18x | 0.46x | 0.52x | 0.71x | 0.72x | 0.73x | 0.67x | 0.53x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangxi Liuzhou Pharm Co Ltd dividends
- Dividend yield
- 6.58%
- Forward dividend
- 0.68 CNY
- Payout ratio
- 63.4%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 450M | 1.13 | 63.4% |
| 2024 | CNY 412M | 1.07 | 48.2% |
| 2023 | CNY 354M | 0.98 | 41.6% |
| 2022 | CNY 174M | 0.48 | 24.8% |
| 2021 | CNY 217M | 0.60 | 38.6% |
| 2020 | CNY 314M | 0.87 | 44.2% |
| 2019 | CNY 159M | 0.44 | 23.2% |
| 2018 | CNY 230M | 0.64 | 43.6% |
| 2017 | CNY 119M | 0.33 | 29.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 24, 2020.
Who owns Guangxi Liuzhou Pharm Co Ltd
- Insiders 31.25%
- Institutions 4.17%
- Public & others 64.58%
- Shares outstanding 397M
- Free float 271M
Guangxi Liuzhou Pharm Co Ltd company profile
- Company name
- Guangxi Liuzhou Pharm Co Ltd
- Ticker
- 603368.SHG
- ISIN
- CNE100001VR3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 5,627
- Fiscal year end
- December
- Address
- No. 68, Guantang Avenue, Liuzhou, China, 545000
- Phone
- 86 77 2251 4508
- Website
- web.lzyy.cn
About Guangxi Liuzhou Pharm Co Ltd
Guangxi LiuYao Group Co., Ltd engages in the manufacturing, wholesale, and retail of pharmaceutical products in China. It offers various types of medicines, medical devices, consumables, diagnostic reagents, other innovative drugs, and self-produced products through online pharmacies and terminal physical pharmacies. The company also offers health consultations and engages in food manufacturing. Guangxi LiuYao Group Co., Ltd was founded in 1981 and is based in Liuzhou, China.
Guangxi Liuzhou Pharm Co Ltd management
8- Mr. Chaoyang ZhuChairman & CEO · born 1966
- Mr. Xiangxing ZengVP, CFO & Accounting Supervisor · born 1982
- Ms. Chunxue TangVP & Employee Representative Director · born 1979
- Mr. Xianhua ZhuVP & Director · born 1982
- Mr. Yang XuBoard Secretary · born 1990
- Mr. Xian Rong TangVice President · born 1972
- Mr. Jun Xiong XiaoVice President · born 1974
- Mr. Zhen LiangVice President · born 1981